Eight weeks of mineralocorticoid blockade does not improve insulin sensitivity in type 2 diabetes.

ABSTRACT: Individuals with type 2 diabetes have an increased risk of cardiovascular disease. A correlation between plasma aldosterone and hyperinsulinemia has been demonstrated in vivo, and hyperinsulinemia and insulin resistance are independently associated with the development of cardiovascular complications. We investigated if mineralocorticoid blockade (Eplerenone) improves insulin sensitivity in individuals with type 2 diabetes compared to healthy controls. We included 13 participants with type 2 diabetes (<5 years; male/female, Caucasians) and 10 healthy control participants (male/female, Caucasians). On 2 experimental days, before and at the end of the 8 weeks of treatment with mineralocorticoid blockade, a two-stage hyperinsulinemic-isoglycemic clamp (20 and 50 mU∙m^-2 min^-1</

SUBMITTER: Finsen SH 

PROVIDER: S-EPMC8339527 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature